Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 17, 2025
Transactions
50
Purchases
50
Sales
0
Purchase value
$1.40M
Sale value
$0.00
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
ADAR1 Capital Management, LLC10% owner
Schneeberger Daniel10% owner
4
Filed Nov 9, 2026Period of report Nov 5, 20260001940272-26-000031
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseNov 5, 2026
Common SharesF1F2F3F4
2,640
$13.0953
$34.57K
98,297
IndirectSee Footnote
Filing footnotes · 4
F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.9500 to $13.3000, inclusive. Each Reporting Person undertakes to provide to Mentari Therapeutics, Inc., any security holder of Mentari Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2On November 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its outstanding common stock. The transaction reported herein occurred on November 5, 2026, after giving effect to the reverse stock split. On November 6, 2026, the Issuer completed its previously announced merger transaction and changed its name from InMed Pharmaceuticals Inc. to Mentari Therapeutics, Inc. and its trading symbol from INM to MTRI. Following completion of the merger and related transactions, the Reporting Persons ceased to beneficially own more than 10% of the Issuer's outstanding common stock and are no longer subject to Section 16.
F3The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F4For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Oct 27, 2026Period of report Oct 23, 20260001940272-26-000028
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 23, 2026
Common SharesF1F2
4
$1.32
$5.28
956,584
IndirectSee Footnote
Filing footnotes · 2
F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by(i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent ofhis/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes ofSection 16 or otherwise.
Filed Oct 20, 2026Period of report Oct 16, 20260001940272-26-000026
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 19, 2026
Common SharesF1F2
1,086
$1.32
$1.43K
956,580
IndirectSee Footnote
PurchaseOct 16, 2026
Common SharesF1F2
1
$1.32
$1.32
955,494
IndirectSee Footnote
Filing footnotes · 2
F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Oct 15, 2026Period of report Oct 13, 20260001940272-26-000025
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 15, 2026
Common SharesF1F2F3
984
$1.3219
$1.30K
955,493
IndirectSee Footnote
PurchaseOct 14, 2026
Common SharesF2F3
8,021
$1.33
$10.67K
954,509
IndirectSee Footnote
PurchaseOct 13, 2026
Common SharesF2F3
564
$1.33
$750.12
946,488
IndirectSee Footnote
Filing footnotes · 3
F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F3For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Oct 8, 2026Period of report Oct 6, 20260001940272-26-000023
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 8, 2026
Common SharesF2F3F4
2,256
$1.3283
$3.00K
945,924
IndirectSee Footnote
PurchaseOct 7, 2026
Common SharesF3F4
3,046
$1.33
$4.05K
943,668
IndirectSee Footnote
PurchaseOct 6, 2026
Common SharesF1F3F4
5,601
$1.3277
$7.44K
940,622
IndirectSee Footnote
Filing footnotes · 4
F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F4For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Oct 5, 2026Period of report Oct 1, 20260001940272-26-000022
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseOct 5, 2026
Common SharesF2F3
18,182
$1.33
$24.18K
935,021
IndirectSee Footnote
PurchaseOct 2, 2026
Common SharesF2F3
8,307
$1.33
$11.05K
916,839
IndirectSee Footnote
PurchaseOct 1, 2026
Common SharesF1F2F3
16,431
$1.3298
$21.85K
908,532
IndirectSee Footnote
Filing footnotes · 3
F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3200 to $1.3300, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F3For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Sep 16, 2026Period of report Sep 14, 20260001940272-26-000021
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseSep 16, 2026
Common SharesF3F4F5
8,340
$1.289
$10.75K
892,101
IndirectSee Footnote
PurchaseSep 15, 2026
Common SharesF2F4F5
54,256
$1.2984
$70.45K
883,761
IndirectSee Footnote
PurchaseSep 14, 2026
Common SharesF1F4F5
28,505
$1.2938
$36.88K
829,505
IndirectSee Footnote
Filing footnotes · 5
F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F5For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Jul 16, 2026Period of report Jul 14, 20260001213900-26-078891
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 16, 2026
Common SharesF1
19
$1.55
$29.45
743,057
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 16, 2026
Common SharesF2
2
$1.55
$3.10
75,019
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJul 15, 2026
Common SharesF1
13,761
$1.55
$21.33K
743,038
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 15, 2026
Common SharesF2
1,389
$1.55
$2.15K
75,017
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJul 14, 2026
Common SharesF1
4,882
$1.55
$7.57K
729,277
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 14, 2026
Common SharesF2
493
$1.55
$764.15
73,628
IndirectBy Vivo Opportunity Cayman Fund, L.P.
Filing footnotes · 2
F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Filed Jul 17, 2026Period of report Jul 15, 20260001940272-26-000010
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 15, 2026
Common SharesF1F2
1,000
$1.555
$1.56K
801,000
IndirectSee Footnote
Filing footnotes · 2
F1The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F2For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Filed Jul 2, 2026Period of report Jun 30, 20260001213900-26-075144
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJul 2, 2026
Common SharesF5F1
1,460
$1.55
$2.26K
724,395
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 2, 2026
Common SharesF5F2
147
$1.55
$227.85
73,135
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJul 1, 2026
Common SharesF4F1
3,946
$1.55
$6.12K
722,935
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJul 1, 2026
Common SharesF4F2
398
$1.55
$616.90
72,988
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 30, 2026
Common SharesF3F1
545
$1.54
$839.30
718,989
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 30, 2026
Common SharesF3F2
55
$1.54
$84.70
72,590
IndirectBy Vivo Opportunity Cayman Fund, L.P.
Filing footnotes · 5
F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
Filed Jun 10, 2026Period of report May 20, 20260001213900-26-067505
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJun 8, 2026
Common SharesF11F1
29,518
$1.52
$44.87K
718,444
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 8, 2026
Common SharesF11F2
2,982
$1.52
$4.53K
72,535
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 5, 2026
Common SharesF10F1
49,966
$1.57
$78.45K
688,926
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 5, 2026
Common SharesF10F2
5,045
$1.57
$7.92K
69,553
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 4, 2026
Common SharesF9F1
6,125
$1.57
$9.62K
638,960
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 4, 2026
Common SharesF9F2
618
$1.57
$970.26
64,508
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 3, 2026
Common SharesF8F1
7,069
$1.55
$10.96K
632,835
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 3, 2026
Common SharesF8F2
714
$1.55
$1.11K
63,890
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 2, 2026
Common SharesF7F1
20,753
$1.52
$31.54K
625,766
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 2, 2026
Common SharesF7F2
2,095
$1.52
$3.18K
63,176
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseJun 1, 2026
Common SharesF6F1
14,838
$1.55
$23.00K
605,013
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseJun 1, 2026
Common SharesF6F2
1,498
$1.55
$2.32K
61,081
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseMay 29, 2026
Common SharesF5F1
16,164
$1.57
$25.38K
590,175
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseMay 29, 2026
Common SharesF5F2
1,632
$1.57
$2.56K
59,583
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseMay 21, 2026
Common SharesF4F1
30,882
$1.69
$52.19K
574,011
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseMay 21, 2026
Common SharesF4F2
3,118
$1.69
$5.27K
57,951
IndirectBy Vivo Opportunity Cayman Fund, L.P.
PurchaseMay 20, 2026
Common SharesF3F1
51,056
$1.56
$79.65K
543,129
IndirectBy Vivo Opportunity Fund Holdings, L.P.
PurchaseMay 20, 2026
Common SharesF3F2
5,154
$1.56
$8.04K
54,833
IndirectBy Vivo Opportunity Cayman Fund, L.P.
Filing footnotes · 11
F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F10The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4.
F11The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4.
F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
F6The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4.
F7The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4.
F8The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4.
F9The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4.
Filed May 21, 2026Period of report May 19, 20260001940272-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseMay 19, 2026
Common SharesF1F4F5
68,551
$1.5998
$109.67K
400,000
IndirectSee Footnote
PurchaseMay 19, 2026
Common SharesF2F4F5
200,000
$1.5604
$312.08K
600,000
IndirectSee Footnote
PurchaseMay 19, 2026
Common SharesF3F4F5
200,000
$1.499
$299.80K
800,000
IndirectSee Footnote
Filing footnotes · 5
F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5700 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5100 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4350 to $1.5700, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
F5For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.